CureVac B.V

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The consensus price target hints at a 139% upside potential for CureVac N.V. (CVAC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe CureVac N.V. (CVAC) Could Rally 139%: Here's is How to Trade

Start Time: 09:00 January 1, 0000 10:01 AM ET CureVac N.V. (NASDAQ:CVAC ) Q3 2022 Earnings Conference Call November 16, 2022, 09:00 AM ET Company Participants Franz-Werner Haas - CEO Pierre Kemula - CFO Ulrike Gnad-Vogt - Interim Chief Development Officer Ronald Plasterk - SVP Science & Innovation Sarah Fakih - VP Corporate Communications and IR Conference Call Participants Geoff Meacham - Bank of America Evan Wang - Guggenheim Jonathan Miller - Evercore Roy Buchanan - JMP Securities Zhiqiang Shu - Berenberg Operator Greetings, and welcome to CureVac Third Quarter and First Nine Months 2022 Financial Results and Business Update.

CureVac N.V. (CVAC) Q3 2022 Earnings Call Transcript

Delivering on broad second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK Phase 1 studies in influenza and COVID-19 on track to deliver clinical data in Q1 2023 Strengthening oncology position based on preparations for new clinical studies with mRNA-based cancer vaccine candidates and positive Phase 1 data on CV8102 Two proof-of-principle studies planned in 2023 to validate and optimize second-generation mRNA backbone in oncology Phase 1 expansion study of non-coding RNA-based candidate CV8102 confirms safety and strong immuno-modulatory characteristics First manufacturing licenses for The RNA Printer® in oncology expected, subject to regulatory approval; applications submitted to regulatory authorities in Q4 2022 Driving innovation at the 10 th International mRNA Health Conference with data on novel LNP delivery system and therapeutic approaches for diseases with high unmet medical need Cash and cash equivalents position of €540.9 million as of September 30, 2022; driven mainly by proceeds related to transfer of production capacity to GSK TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 16, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced financial results for the third quarter and first nine months of 2022 and provided a business update.

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update

Data confirm CV8102's safety and ability to strongly mobilize the immune system against tumors Final data of complete Phase 1 dose-escalation and expansion study expected in H1 2023 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 11, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced data from the Phase 1 expansion study of CV8102, the company's non-coding RNA candidate in oncology.

CureVac Presents Preliminary Data from Phase 1 Study Expansion of Oncology Candidate CV8102

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 10, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the third quarter of 2022 on Wednesday, November 16, 2022.

CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022

Agenus

Dynavax Technologies

Immunocore Holdings

New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well amid the volatility.

Bet on These 4 Biotech Stocks With Bright Prospects

Affirm

Asana

Compass Minerals

Coinbase

GoodRx Holdings

Lightspeed Commerce Inc

Oatly

RLX Technology

TuSimple Holdings

Unity Software

Upstart Holdings

This year's market downturn has hit the IPO market hard.

Jim Cramer's 'dirty dozen' stocks that underscore the carnage in the IPO market

CureVac N.V. (CVAC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

Here's Why CureVac N.V. (CVAC) is Poised for a Turnaround After Losing 20.9% in 4 Weeks

Delivering on broad 2022 second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK; new candidates in COVID-19 and influenza enter clinical studies Phase 1 initiated for modified COVID-19 vaccine candidate CV0501, targeting Omicron variant Phase 1 initiated for modified influenza vaccine candidate FLU SV mRNA Accelerating oncology strategy with complementary technology platforms and strong leadership support Acquisition of Frame Cancer Therapeutics adds advanced genomics and bioinformatics capabilities to feed pipeline of cancer vaccine candidates Appointment of Dr. Myriam Mendila, M.D., as Chief Development Officer adds international experience and expertise in building a broad oncology product portfolio Cash position of €573.6 million as of June 30, 2022; decreasing headwind of wind-down costs for first-generation COVID-19 vaccine program TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 18, 2022 / CureVac N.V.

CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update

Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines Milestone demonstrates CureVac's continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 18, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the start of a Phase 1 study of the modified COVID-19 mRNA vaccine candidate CV0501, administered as a booster dose to previous COVID-19 vaccination.

CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

BioNTech SE

Pfizer

COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac.

BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims

The mean of analysts' price targets for CureVac N.V. (CVAC) points to a 96.4% upside in the stock.

Wall Street Analysts Predict a 96% Upside in CureVac N.V. (CVAC): Here's What You Should Know

CureVac (NASDAQ:CVAC) has filed a patent lawsuit in Germany against BioNTech (NASDAQ:BNTX) in what is one of the first court cases in which a company has sued another for using mRNA technology in developing a coronavirus vaccine. According to Germany-based CureVac, it will "assert its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to Covid-19 vaccine development", and is seeking "fair compensation" from BioNTech and two subsidiaries.

BioNTech sued by CureVac over its mRNA technology

CureVac N.V. (NASDAQ: CVAC) has moved to assert its intellectual property rights, accumulated over two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development.

CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech

BERLIN (Reuters) -CureVac has filed a lawsuit in Germany against BioNTech and two of its subsidiaries, seeking "fair compensation" for what it said was infringement of its intellectual property rights, the vaccine maker said on Tuesday.

CureVac files patent lawsuit in Germany against BioNTech

CureVac says its intellectual property portfolio protects multiple inventions that are considered essential to Pfizer and BioNTech's Covid-19 vaccine.

CureVac Sues BioNTech Over mRNA and Covid Vaccines. Pfizer Stock Isn't Spared.

Shares of BioNTech SE BNTX, +5.63% fell 0.9% in premarket trading Tuesday, after CureVac N.V. CVAC, +4.63% filed in Germany a patent infringement suit against the biotechnology company.

BioNTech stock falls after CureVac files suit, saying COVID vaccine infringes patents

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 5, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA") today announced that it has moved to assert its intellectual property rights, accumulated over more than two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development.

CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech

Acquisition extends CureVac's capabilities and adds key competencies to further accelerate oncology strategy for new therapies that enable patients' immune systems to fight cancer Frame's platform offers potential to develop off-the-shelf and personalized cancer vaccines targeting novel families of neoantigens TÜBINGEN, GERMANY and AMSTERDAM, NETHERLANDS / ACCESSWIRE / June 8, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced its acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types.

CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform

Myriam Mendila appointed as Chief Development Officer starting from February 1, 2023 Klaus Edvardsen returning to Denmark after holding numerous leadership positions in the U.S. and Europe Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim Chief Development Officer TÜBINGEN, DEUTSCHLAND and BOSTON, MA / ACCESSWIRE / June 8, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA") today announced that Chief Development Officer Klaus Edvardsen will leave the company on June 30, 2022.

CureVac Announces Changes of CDO - Myriam Mendila to Succeed Klaus Edvardsen

The average of price targets set by Wall Street analysts indicates a potential upside of 53.3% in CureVac N.V. (CVAC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 53% Upside in CureVac N.V. (CVAC): Can the Stock Really Move This High?

CureVac is broadening its foundation in oncology, leveraging recent progress with its second-generation mRNA backbone The partnership combines CureVac's mRNA technology with myNEO's platform for the discovery and selection of tumor antigens predicted to elicit strong immune responses Together with myNEO, CureVac aims to identify specific antigens for the development of novel mRNA cancer vaccines TÜBINGEN, GERMANY and GHENT, BELGIUM / ACCESSWIRE / May 25, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), and myNEO N.V.

CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development

Progressing broad vaccine development program in collaboration with GSK, with second-generation candidates in Phase 1 clinical trials for COVID-19 and influenza CureVac eligible to a €10 million milestone payment from GSK for the initiation of the influenza clinical trial Increasing momentum in oncology with access to neoantigen technologies to feed meaningful pipeline of cancer vaccine candidates Partnership with myNEO to develop novel mRNA cancer vaccines leveraging myNEO's advanced platform for tumor antigen discovery and selection Cash position of €658.2 million as of March 31, 2022, impacted by wind-down costs for first-generation COVID-19 vaccine program TÜBINGEN, GERMANY and BOSTON MA / ACCESSWIRE / May 25, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced financial results for the first quarter of 2022 and provided a business update.

Curevac Announces Financial Results For The First Quarter Of 2022 And Provides Business Update

CureVac NV (NASDAQ:CVAC ) Q4 2021 Earnings Conference Call April 28, 2022 9:00 AM ET Company Participants Sarah Fakih - VP Corporate Communications & IR Franz-Werner Haas - CEO Klaus Edvardsen - Chief Development Officer Pierre Kemula - CFO Conference Call Participants Douglas Buchanan - JMP Securities Eun Yang - Jefferies Zhiqiang Shu - Berenberg Operator Greetings. Welcome to the CureVac Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call.

CureVac NV (CVAC) CEO Franz-Werner Haas on Q4 2021 Results - Earnings Call Transcript

- Executing on broad vaccine development program, with new clinical studies in COVID-19 and influenza together with GSK to validate advanced second-generation mRNA backbone - Initiated Phase 1 dose-escalation study in COVID-19 with CV2CoV, validating mRNA backbone for further variant adaptation - Fully recruited Phase 1 dose-escalation study in influenza with differentiated multivalent vaccine candidate, CVSQIV, confirmed good tolerability profile across all doses - Bivalent approach for combined Beta/Delta-COVID-19 vaccine candidate shows promising preclinical data, with high neutralizing capacity against each variant, as well as against Omicron - Increasing momentum in oncology pipeline by focusing on new avenues for T cell activation as well as access to novel classes of antigens and antigen discovery platforms - Launched fully owned subsidiary, CureVac RNA Printer GmbH, to accelerate development of The RNA Printer(R) with dedicated infrastructure and experienced management - Executed contract with German government for pandemic preparedness together with GSK, providing access to developed vaccines and CureVac's manufacturing capacity - Cash position of €811.5 million as of December 31, 2021. EU confirms no obligation to repay upfront payment for Advanced Purchase Agreement for first-generation candidate, CVnCoV TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 28, 2022 / CureVac N.V.

News for CureVac B.V Stock (CVAC)